Ironwood Pharmaceuticals Begins Phase I Trial of Investigational IW-2143 Anxiety Drug in US

ADELAIDE, Australia, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc (Nasdaq:IRWD) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has begun in the US.